Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 3, 2013, Pages 284-296

  Tarantino, Michael D ^a   Fogarty, Patrick ^b   Mayer, Bhabita ^c   Vasey, Sandra Y ^d   Brainsky, Andres ^d  

^a UNIVERSITY OF ILLINOIS   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

bleeding disorders; platelets; thrombocytopenia

Indexed keywords

ELTROMBOPAG; PLACEBO;

ADULT; AGED; ARTICLE; BLEEDING DISORDER; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZOATES; BLOOD PLATELETS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMORRHAGE; HUMANS; HYDRAZINES; MALE; MIDDLE AGED; PLATELET COUNT; PROSPECTIVE STUDIES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, THROMBOPOIETIN;

EID: 84875870812     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32835fac99     Document Type: Article

References (20)

1. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88:3-40. (Pubitemid 26230668)
2. BCSH. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120:574-596.
3. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113:2386-2393.
4. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346:995-1008.
5. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000; 160:1630- 1638. (Pubitemid 30367902)
6. Stevens W, Koene H, Zwaginga JJ, Vreudenhil G. Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. Neth J Med 2006; 64:356-363. (Pubitemid 44811211)
7. Fontana V, Jy W, Ahn ER, Dudkiewicz P, Horstman LL, Duncan R, Ahn YS. Increased procoagulant cell-derived microparticles (C-MP) in splenectomized patients with ITP. Thromb Res 2008; 122:599- 603.
8. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115:168-186.
9. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357:2237-2247. (Pubitemid 350190754)
10. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373:641-648.
11. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377:393- 402.
12. Bussel JB, Psaila B, Saleh MN, Vasey S, Mayer B, Stone NL, Arning M. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura. Blood 2008; 112:Abstract 3431.
13. Saleh MN, Cheng G, Bussel JB, Sun H, Mayer B, Bailey C, Brainsky A. EXTEND study update: safety and efficacy of eltrombopag in adults with chronic immune thrombocytopenia (ITP) from June 2006 to February 2010. Blood 2010; 116:Abstract 67.
14. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6:114. (Pubitemid 30082329)
15. Marie I, Maurey G, Hervé F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006; 155:714- 721. (Pubitemid 44352551)
16. Huerta C, Johansson S, Wallander MA, Wallander MA, Garci'a Rodri'guez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167:935-943. (Pubitemid 46762756)
17. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363:1889-1899.
18. Bussel JB, Zhang J, Tang S, McIntosh J, Kuter DJ. A randomized, doubleblind, placebo-controlled phase II trial on the efficacy, safety and tolerability of E5501 (AKR501) in subjects with chronic immune thrombocytopenia (ITP). Blood 2010; 116:Abstract 71.
19. Brynes RK, Orazi A, Verma S, Brainsky A, Bailey C, Bakshi K. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenic purpura (ITP) treated with eltrombopag - data from the EXTEND study. Blood 2011; 118:Abstract 528.
20. Cooper N, Wong R, Brainsky A, Bailey C. Rate of cataracts across the eltrombopag clinical studies in patients with chronic immune thrombocytopenia. Blood 2011; 118:Abstract 1164.